



Erratum: Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma

Frontiers Pharmacology Editorial Office*

Pharmacology Editorial Office, Frontiers Media SA, Lausanne, Switzerland

Keywords: cyclooxygenases (COXs), hydrogen sulfide (H2S), non-steroidal anti-inflammatory drugs (NSAIDs), melanoma, target-therapy, apoptosis

OPEN ACCESS

Approved by:

An Erratum on

Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence:

Frontiers Pharmacology Editorial Office pharmacology.editorial.office@ frontiersin.org

Specialty section:

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

> Received: 20 February 2019 Accepted: 20 February 2019 Published: 26 February 2019

Citation:

Frontiers Pharmacology Editorial Office (2019) Erratum: Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma. Front. Pharmacol. 10:213. doi: 10.3389/fphar.2019.00213 Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma

Ercolano, G., De Cicco, P., Frecentese, F., Saccone, I., Corvino, A., Giordano, F., et al. (2019). Front. Pharmacol. 10:66. doi: 10.3389/fphar.2019.00066

The statement declaring the relationship between the handling editor and two of the authors has been clarified for transparency of the process. The updated statement should read, in full:

After the conclusion of the peer review, the handling editor noticed and declared a collaboration and shared affiliation with two of the authors, VaC and ViC. These authors provided an additional analysis requested by a reviewer during review. They were later added as co-authors and identified to the editor after the provisional acceptance of the manuscript. Under these exceptional circumstances, the relationship did not affect the objectivity of the review process, and this situation is being declared for transparency.

The publisher apologizes for this oversight. The original article has been updated.

Copyright © 2019 Frontiers Pharmacology Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

1